Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.

Abstract

The prevalence of diabetes mellitus and its complications, such as diabetic nephropathy (DN), is rising worldwide and prevention and treatment are therefore becoming increasingly important. Therapy of DN is particularly important for patients who do not adequately respond to angiotensin receptor blocker (ARB) treatment. Novel approaches include the stimulation of soluble guanylate cyclase (sGC) as it is reported to have beneficial effects on cardiac and renal damage. We aimed to investigate the effects of the sGC stimulator riociguat and ARB telmisartan on kidney function and structure in a hypertensive model of diabetic nephropathy. Seventy-six diabetic male eNOS knockout C57BL/6J mice were randomly divided after having received streptozotocin: telmisartan (1 mg/kg/d), riociguat (3 mg/kg/d), riociguat+telmisartan (3+1 mg/kg/d), and vehicle. Fourteen mice were used as non-diabetic controls. Treatment duration was 11 weeks. Glucose concentrations were increased and similar in all diabetic groups. Telmisartan insignificantly reduced blood pressure by 5.9 mmHg compared with diabetic controls (111.2±2.3 mmHg vs. 117.1±2.2 mmHg; p = 0.071). Treatment with riociguat both alone and in combination with telmisartan led to a significant reduction of blood pressure towards diabetic vehicle (105.2±2.5 mmHg and 105.0±3.2 mmHg, respectively, vs. 117.1±2.2 mmHg). Combined treatment also significantly decreased albuminuria compared with diabetic controls (47.3±9.6 µg/24 h vs. 170.8±34.2 µg/24 h; p = 0.002) reaching levels similar to those of non-diabetic controls (34.4±10.6 µg/24 h), whereas the reduction by single treatment with either telmisartan (97.8±26.4 µg/24 h) or riociguat (97.1±15.7 µg/24 h) was not statistically significant. The combination treatment led to a significant (p<0.01) decrease of tissue immunoreactivity of malondialdehyde, as consequence of reduced oxidative stress. In conclusion, stimulation of sGC significantly reduced urinary albumin excretion in diabetic eNOS knockout mice treated already with ARB. Thus, this new drug class on top of standard ARBs administration may offer a new therapeutic approach for patients resistant to ARB treatment.

• Authors: Ina M Ott, Markus L Alter, Karoline von Websky, Axel Kretschmer, Oleg Tsuprykov, Yuliya Sharkovska, Katharina Krause-Relle, Jens Raila, Andrea Henze, Johannes-Peter Stasch, Berthold Hocher
• Journal: PloS one (PLoS One) Vol. 7 Issue 8 Pg. e42623 ( 2012) ISSN: 1932-6203 [Electronic] United States
• PMID: 22900035 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiotensin II Type 1 Receptor Blockers
• Benzimidazoles
• Benzoates
• Biomarkers
• Blood Glucose
• Pyrazoles
• Pyrimidines
• Receptors, Angiotensin
• Receptors, Cytoplasmic and Nuclear
• Nitric Oxide Synthase Type III
• Guanylate Cyclase
• Soluble Guanylyl Cyclase
• riociguat
• Telmisartan

Topics

• Angiotensin II Type 1 Receptor Blockers (administration & dosage, pharmacology)
• Animals
• Benzimidazoles (administration & dosage, pharmacology)
• Benzoates (administration & dosage, pharmacology)
• Biomarkers (blood)
• Blood Glucose (drug effects)
• Blood Pressure (drug effects)
• Diabetic Nephropathies (drug therapy, genetics, metabolism, mortality)
• Disease Models, Animal
• Guanylate Cyclase (antagonists & inhibitors, metabolism)
• Kidney Function Tests
• Male
• Mice
• Mice, Inbred C57BL
• Mice, Knockout
• Nitric Oxide Synthase Type III (genetics, metabolism)
• Organ Size (drug effects)
• Pyrazoles (administration & dosage, pharmacology)
• Pyrimidines (administration & dosage, pharmacology)
• Receptors, Angiotensin (metabolism)
• Receptors, Cytoplasmic and Nuclear (antagonists & inhibitors, metabolism)
• Soluble Guanylyl Cyclase
• Telmisartan